STAMFORD, Conn., May 06, 2024 Cara Therapeutics, Inc. , a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus,.
STAMFORD, Conn., April 02, 2024 Cara Therapeutics, Inc. , a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from.
Cara Therapeutics To Present At The 23Rd Annual Needham Virtual Healthcare Conference menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
– Oral difelikefalin as adjunct to topical corticosteroids did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in pruritus.
– Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 – – Key data readouts for all.